News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
576,746 Results
Type
Article (22610)
Company Profile (164)
Press Release (553638)
Multimedia
Podcasts (109)
Webinars (17)
Section
Business (198071)
Career Advice (1094)
Deals (31308)
Drug Delivery (130)
Drug Development (63861)
Employer Resources (74)
FDA (11806)
Job Trends (10651)
News (283856)
Policy (23499)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (965)
Accelerated approval (47)
ADA (33)
Adcomms (23)
Allergies (126)
Alliances (39792)
ALS (151)
Alzheimer's disease (1331)
Antibody-drug conjugate (ADC) (450)
Approvals (12348)
Artificial intelligence (534)
ASCO (234)
Autoimmune disease (307)
Automation (42)
Bankruptcy (322)
Best Places to Work (8107)
BIO (60)
Biologics (3)
BIOSECURE Act (23)
Biosimilars (190)
BioSpace Insights (91)
Biotechnology (100)
Bladder cancer (173)
Brain cancer (43)
Breast cancer (609)
Cancer (4931)
Cardiovascular disease (398)
Career advice (928)
Career pathing (30)
CAR-T (286)
CDC (23)
Celiac Disease (1)
Cell therapy (732)
Cervical cancer (42)
Clinical research (57049)
Collaboration (1781)
Commercialization (7)
Company closure (5)
Compensation (1524)
Complete response letters (72)
COVID-19 (1543)
CRISPR (80)
C-suite (1145)
Cystic fibrosis (99)
Data (6872)
Decentralized trials (1)
Denatured (24)
Depression (143)
Dermatology (82)
Diabetes (507)
Diagnostics (5007)
Digital health (50)
Diversity (8)
Diversity, equity & inclusion (20)
Drug discovery (283)
Drug pricing (183)
Drug shortages (29)
Duchenne muscular dystrophy (257)
Earnings (82894)
Editorial (62)
Employer branding (8)
Employer resources (78)
Events (98699)
Executive appointments (998)
FDA (15086)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (27)
Funding (1364)
Gene editing (180)
Generative AI (50)
Gene therapy (515)
GLP-1 (851)
Government (2290)
Grass and pollen (3)
Guidances (355)
Healthcare (11818)
Hematology (126)
HIV (72)
Huntington's disease (41)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (99)
Immunology and inflammation (274)
Immuno-oncology (102)
Indications (183)
Infectious disease (1824)
Inflammatory bowel disease (180)
Inflation Reduction Act (9)
Influenza (101)
Intellectual property (302)
Interviews (147)
IPO (14627)
IRA (44)
Job creations (2777)
Job search strategy (804)
JPM (48)
Kidney cancer (21)
Labor market (85)
Layoffs (352)
Leadership (40)
Legal (6382)
Licensing (11)
Liver cancer (67)
Longevity (27)
Lung cancer (742)
Lymphoma (367)
Machine learning (42)
Management (30)
Manufacturing (967)
Marketing (11)
MASH (191)
Medical device (10075)
Medtech (10241)
Mergers & acquisitions (17877)
Metabolic disorders (1360)
mRNA (131)
Multiple sclerosis (158)
NASH (16)
Neurodegenerative disease (351)
Neuropsychiatric disorders (92)
Neuroscience (2621)
Neurotech (1)
NextGen: Class of 2026 (4036)
Non-profit (1356)
Now hiring (55)
Obesity (638)
Opinion (227)
Ovarian cancer (182)
Pain (231)
Pancreatic cancer (247)
Parkinson's disease (294)
Partnered (26)
Patents (616)
Patient recruitment (650)
Peanut (39)
People (50691)
Pharmaceutical (43)
Pharmacy benefit managers (29)
Phase 1 (18210)
Phase 2 (25323)
Phase 3 (18227)
Pipeline (9118)
Policy (255)
Postmarket research (1796)
Preclinical (7415)
Press Release (57)
Prostate cancer (252)
Psychedelics (45)
Radiopharmaceuticals (275)
Rare diseases (916)
Real estate (4231)
Recruiting (38)
Regulatory (19447)
Reports (40)
Research institute (1021)
Resumes & cover letters (169)
Rett syndrome (42)
RNA editing (16)
RSV (76)
Schizophrenia (170)
Series A (260)
Series B (173)
Service/supplier (7)
Sickle cell disease (88)
Special edition (25)
Spinal muscular atrophy (116)
Sponsored (25)
Startups (2785)
State (1)
Stomach cancer (15)
Supply chain (104)
Tariffs (98)
The Weekly (83)
Vaccines (636)
Venture capital (112)
Weight loss (425)
Women's health (102)
Worklife (11)
Date
Today (64)
Last 7 days (317)
Last 30 days (1995)
Last 365 days (24393)
2026 (15979)
2025 (24223)
2024 (28295)
2023 (31975)
2022 (41470)
2021 (44046)
2020 (40434)
2019 (29790)
2018 (22671)
2017 (24175)
2016 (23165)
2015 (28871)
2014 (24997)
2013 (21161)
2012 (23272)
2011 (23590)
2010 (22738)
Location
Africa (466)
Alabama (79)
Alaska (4)
Arizona (329)
Arkansas (12)
Asia (34113)
Australia (3583)
California (12898)
Canada (3535)
China (1684)
Colorado (575)
Connecticut (483)
Delaware (280)
Europe (52903)
Florida (1951)
Georgia (397)
Hawaii (3)
Idaho (47)
Illinois (823)
India (99)
Indiana (417)
Iowa (18)
Japan (568)
Kansas (110)
Kentucky (35)
Louisiana (34)
Maine (29)
Maryland (1429)
Massachusetts (8855)
Michigan (330)
Minnesota (600)
Mississippi (5)
Missouri (94)
Montana (22)
Nebraska (22)
Nevada (124)
New Hampshire (72)
New Jersey (3262)
New Mexico (29)
New York (3258)
North Carolina (1504)
North Dakota (4)
Northern California (6471)
Ohio (345)
Oklahoma (16)
Oregon (21)
Pennsylvania (2454)
Puerto Rico (29)
Rhode Island (38)
South America (716)
South Carolina (79)
South Dakota (1)
Southern California (5320)
Tennessee (139)
Texas (2011)
United States (43389)
Utah (381)
Vermont (1)
Virginia (188)
Washington D.C. (58)
Washington State (993)
West Virginia (2)
Wisconsin (90)
Wyoming (3)
576,746 Results for "china pharma holdings inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
China
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
When signing a biotech licensing deal in China, experts say that pharma’s patent attorneys need to understand the geopolitical risk of the BIOSECURE Act.
July 28, 2026
·
7 min read
·
Annalee Armstrong
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
July 10, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
August 13, 2026
·
5 min read
Press Releases
China SXT Pharmaceuticals, Inc. Announces Share Consolidation
August 5, 2026
·
3 min read
China
Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent
Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.
May 29, 2026
·
2 min read
·
Tristan Manalac
China
BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech
Speaking to media on Tuesday, BIO CEO John Crowley complimented China’s rise as a biotech powerhouse but said U.S. policy needs to protect and maintain America’s lead.
June 24, 2026
·
2 min read
·
Annalee Armstrong
Editorial
Biotech’s China problem: An issue of national security or economic value for the US?
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
July 2, 2026
·
6 min read
·
Jef Akst
Obesity
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
July 7, 2026
·
4 min read
·
Gabrielle Masson
Press Releases
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
May 5, 2026
·
8 min read
China
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
Ivonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines over time.
August 17, 2026
·
2 min read
·
Annalee Armstrong
1 of 57,675
Next
